Pages that link to "Q41231593"
Jump to navigation
Jump to search
The following pages link to Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate (Q41231593):
Displaying 50 items.
- Oxaliplatin: available data in non-colorectal gastrointestinal malignancies (Q30666815) (← links)
- Oxaliplatin: a new agent for colorectal cancer (Q31935266) (← links)
- Modeling biological rhythms in failure time data (Q33262921) (← links)
- Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study (Q33344357) (← links)
- Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (Q33358104) (← links)
- Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma (Q33359823) (← links)
- A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients (Q33366008) (← links)
- Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study (Q33373017) (← links)
- Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study (Q33374394) (← links)
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. (Q33376718) (← links)
- Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study (Q33379271) (← links)
- Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study (Q33383287) (← links)
- Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer (Q33386361) (← links)
- Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis (Q33389036) (← links)
- Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen) (Q33393039) (← links)
- Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib (Q33400294) (← links)
- Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis (Q33403870) (← links)
- Oxaliplatin: a review of its use in the management of metastatic colorectal cancer (Q33688811) (← links)
- Cancer chronotherapy (Q33742395) (← links)
- Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches (Q33811941) (← links)
- Oxaliplatin: pharmacokinetics and chronopharmacological aspects (Q33834597) (← links)
- Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer (Q33879736) (← links)
- Oxaliplatin clinical activity: a review (Q33998344) (← links)
- Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer (Q34070317) (← links)
- Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer (Q34289631) (← links)
- Treatment of liver metastases from colorectal cancer: what is the best approach today? (Q34351014) (← links)
- Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (Q34504536) (← links)
- FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O (Q34565268) (← links)
- New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer (Q34572041) (← links)
- Circadian chronotherapy for human cancers (Q34572050) (← links)
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (Q34594956) (← links)
- Particular aspects of platinum compounds used at present in cancer treatment (Q34671647) (← links)
- Oxaliplatin: results in colorectal carcinoma. (Q34979779) (← links)
- Cancer chronotherapy: principles, applications, and perspectives (Q35030286) (← links)
- Platinum-based chemotherapy in metastatic breast cancer: current status. (Q35650449) (← links)
- Oxaliplatin (L-OHP): a new reality in colorectal cancer (Q36291590) (← links)
- Oxaliplatin in practice (Q36291603) (← links)
- Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group (Q36459767) (← links)
- A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer (Q36594055) (← links)
- Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. (Q36615060) (← links)
- Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. (Q36623730) (← links)
- Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study (Q36626112) (← links)
- Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial (Q36636872) (← links)
- Hypersensitivity reactions related to oxaliplatin (OHP). (Q36671350) (← links)
- Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer (Q36671857) (← links)
- Oxaliplatin in the treatment of colorectal cancer (Q36788436) (← links)
- Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy (Q36936011) (← links)
- Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma (Q37134006) (← links)
- A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen (Q37383249) (← links)
- Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics (Q37896345) (← links)